Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Is 50 Really the New 30? Your Immune System May Not Think So

Business Wire September 30, 2015

Pfizer Declares 28-Cent Fourth-Quarter 2015 Dividend

Business Wire September 25, 2015

Merck KGaA, Darmstadt, Germany, and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

Business Wire September 25, 2015

Merck KGaA, Darmstadt, Germany, and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Business Wire September 24, 2015

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Business Wire September 24, 2015

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Business Wire September 24, 2015

Pfizer's Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

Business Wire September 24, 2015

New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

PR Newswire September 23, 2015

XRpro Sciences Completes Name Change to Icagen, Inc. Following Acquisition of Pfizer Ion Channel Platform Assets

PR Newswire September 22, 2015

New Centrum® VitaMints® Offer a Refreshingly New Way to Take a Multivitamin

Business Wire September 22, 2015

Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tofacitinib in Adults with Moderate-to-Severe Ulcerative Colitis

Business Wire September 21, 2015

Pfizer Inc. Announces Results of Early Tenders and Consents in Exchange Offers

Business Wire September 18, 2015

Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts

Business Wire September 15, 2015

Merck KGaA, Darmstadt, Germany and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015

Business Wire September 11, 2015

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire September 10, 2015

Pfizer Inc. Commences Exchange Offers for Hospira Notes

Business Wire September 3, 2015

Pfizer Completes Acquisition of Hospira

Business Wire September 3, 2015

Activision Blizzard, United Continental Holdings Set to Join the S&P 500

PR Newswire August 27, 2015

Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor-Positive Early Breast Cancer

Business Wire August 26, 2015

Pfizer (PFE) says $15.23B Hospira deal gets final regulatory approvals

Canadian Press August 25, 2015